[Click e-Stock] "MECASYS Turns Profitable in Q1...U.S. Expansion Accelerates on FDA Approval"

On May 14, independent research firm ValueFinder stated that MECAS achieved a turnaround in its first-quarter results this year and projected that the company's entry into the U.S. market will accelerate, based on its formal product approval process for respiratory therapy devices from the U.S. Food and Drug Administration (FDA).

Lee Chungheon, a researcher at ValueFinder, analyzed that MECAS recorded sales of 3.9 billion won in the first quarter of this year, marking a 33.4% increase compared to the same period last year. Operating profit reached 400 million won, successfully returning to profitability.

He commented, "More than half of domestic sales come from consumables, providing a stable recurring revenue base. Since overseas sales have not yet been fully reflected, once entry into the U.S. and European markets becomes visible, there is ample potential for additional top-line growth and improved profitability."

MECAS, established in 1988, is a specialized medical device company engaged in respiratory therapy devices and patient monitoring systems. The company recently obtained the formal FDA 510(k) approval for its respiratory therapy device 'HFT750U,' which is expected to secure a regulatory framework for continuous sales within the U.S.

In particular, the company is pursuing an exclusive consumables supply agreement with a major global distributor in the U.S., which is expected to accelerate its market share expansion.

The HFT750U is a device equipped with both high-flow nasal cannula functionality and non-invasive ventilator functions. Its key feature is that it can be used not only in intensive care units (ICUs) but also in general wards, broadening its range of applications.

ValueFinder anticipated that once product approval and consumables supply agreements are finalized, MECAS will be able to build a sustainable revenue base in the U.S. market, moving beyond one-off demand such as during pandemics.

Researcher Lee Chungheon explained, "This turnaround to profitability in the first quarter is significant because it is not just a temporary recovery—the foundation of consumables sales, combined with rising device demand, has begun to contribute meaningfully to profit growth."

He further analyzed, "The HFT750U has already acquired ISO biocompatibility certification in the U.S. as well as CE certification in Europe, increasing the likelihood of simultaneous entry into both the North American and European markets."

He added, "If the company collaborates with AI startup DeepMatrix to establish a program based on respiratory therapy data, it could be revalued as a data-driven digital healthcare platform provider, surpassing its status as a conventional medical device company."

This content was produced with the assistance of AI translation services.